Kornimate/medical-research-clean huggingface dataset:
evaluation of the effectiveness of the video prepared to raise cervical cancer awareness in women between the ages of 18 and 65 via social media.

Conditions: Being a Woman Aged 18-65

Summary: this research, a quasi-experimental study based on the comparison of the pre-test and post-test results of individuals in a single group is conducted to raise awareness about cervical cancer in women aged 18-65 years. the questionnaire includes 32 questions about the individual's socio-demographic characteristics, pregnancy, and sexual life information, cervical cancer, pap-smear test, and hpv vaccine information, as well as a 27-item 3-point likert type to measure cervical cancer risk factors, symptoms, and prevention. a survey form consisting of 61 questions, consisting of 2 questions and 2 guestions for evaluating the animated training video, and an informative animated training video of 4 minutes and 33 seconds constituted the data collection tools. during the covid-19 pandemic, the study has completed with 433 people who participated voluntarily by directing the participants via online platforms (whatsapp / instagram / e-mail) using the snowball sampling method of survey applications. the women who participated in the research completed the first part by watching the informative animated training video at the end of the questionnaire form.


Eligibility criteria:
inclusion criteria: * be 18-65 years old * being literate * using whatsapp / instagram / email * will volunteer to participate in the research. exclusion criteria: * attending the pre-test but not participating in the post-test * filling the survey form incompletely.

Keywords: cervical cancer social media awareness hpv pap-smear
robotic-assisted left hemicolectomy for left colon cancer

Conditions: Colon Cancer

Summary: the main goal of this study is to clarify if robotic-assisted surgery could become the standard approach in patients undergoing left colonic resection. patient candidates to left colonic resection were randomly assigned to robotic(ral) or laparoscopic(ll) approach. the surgical staff who were not involved in the study registered 30-day postoperative morbidity. cost-benefit analysis was based on hospital days. long-term morbidity, quality of life, and 5-year survival have also been evaluated

robotic-assisted left hemicolectomy as advantages on showing the inferior mesenteric artery (ima), protection of autonomic nerve compare to laparoscopic approach. our experience found that operational flexibility was advantage without surgeon's position exchange.

Eligibility criteria:
inclusion criteria: colon cancer adenocarcinoma the tumor located between the descending colon and the right 1/3 of transverse colon tumors t3,т4а,b n0-2 tolerance of chemotherapy ecog 0-2 exclusion criteria: with distant metastases tumors t1-2 complications of tumor women during pregnancy
circahealth development and evaluation

Conditions: Health Behavior; Health Knowledge, Attitudes, Practice; Circadian Rhythm

Summary: this study evaluates the feasibility, acceptability, and efficacy of an online education course about circadian rhythms and health. half of participants will be enrolled into the online course and the other half will receive materials on sleep hygiene as a control.

this is a pilot randomized controlled study that aims to develop circahealth: an online course on practices, known as circadian hygiene, that promote circadian rhythm alignment and minimize circadian rhythm misalignment. the project also will determine the feasibility, acceptability, and preliminary effects of circahealth in improving circadian rhythm related measures in university of miami miller school of medicine medical students. the educational videos will be incorporated into a six-module online course which contains additional educational and behavior modification tools. medical students (n = 40) will be recruited via email and randomized to receive circahealth or materials from the national sleep foundation and/or the american academy of sleep medicine. sleep, mood, and circadian hygiene knowledge, behaviors, and attitudes will be assessed at baseline and four weeks post intervention. feasibility will be determined by circahealth module completion rates, and acceptability will be assessed via a self-report survey. changes in sleep quality measures between groups will determine the preliminary efficacy of circahealth.

Eligibility criteria:
inclusion criteria: * medical students, 1st through 4th year, at the university of miami miller school of medicine willing to participate in surveys and the circahealth course.

Keywords: circadian rhythm education student burnout sleep hygiene
evaluation of crs-207 with pembrolizumab in previously treated malignant pleural mesothelioma (mpm)

Conditions: Malignant Pleural Mesothelioma

Summary: the purpose of this study is to evaluate whether crs-207 with pembrolizumab is safe and effective in adults with mpm who have failed prior anti-cancer therapy.

the population for this study will consist of approximately 35 adults with histologically-confirmed mpm (epithelial or biphasic) whose disease has progressed after 1-2 prior anti-cancer therapies.

Eligibility criteria:
inclusion criteria: 1. histologically-confirmed epithelial or biphasic mpm; biphasic tumors must have a predominantly (≥50%) epithelial component 2. no more than 2 prior lines of anti-cancer therapy, one of which must have included pemetrexed and a platinum. 3. eastern cooperative oncology group (ecog) performance status of 0 or 1 4. adequate organ and marrow function 5. adequate lung function; forced vital capacity (fvc) and forced expiratory volume in 1 second (fev1) ≥ 45% of predicted value as measured by spirometry; and oxygen saturation ≥ 90% on room air exclusion criteria 1. pleurodesis within 14 days prior to first dose of study drug 2. receiving tumor necrosis factor (tnf) pathway inhibitors, pi3 kinase inhibitors, systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug 3. active secondary malignancy 4. prior anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug, or not recovered from adverse effects due to agents administered more than 4 weeks earlier 5. prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study drug 6. history of (non-infectious) pneumonitis that required steroids or current pneumonitis 7. prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2 agent, or agents targeting other checkpoint pathways (e.g. ctla-4) 8. prior immunotherapy with crs-207 or any other listeria-based agent, therapeutic cancer vaccine, or adoptive t cell immunotherapy 9. implanted medical devices that pose high risks for colonization and cannot be easily removed (e.g., artificial heart valves, pacemakers, prosthetic joints, orthopedic screw(s), metal plate(s)) if infection occurs. other common devices such as venous access devices (e.g., port-a-cath or mediport) may be permitted as well as arterial and venous stents and dental and breast implants that were placed more than 3 months prior to first dose of study drug.
colchicine in postoperative fontan patients

Conditions: Single-ventricle; Heart Diseases

Summary: the investigators found that there is inflammation in the chest drainage in patients after the fontan operation. the investigators want to test the theory that colchicine, an anti- inflammatory medication, can decrease the inflammation in the chest tube drainage after the fontan operation, and can decrease the amount of time that patients having this surgery will have drainage.


Eligibility criteria:
inclusion criteria: * ages 20 months to 5 years and 364 days are eligible * diagnosed with single ventricle heart disease requiring fontan palliation * undergoing fontan palliation at the university of michigan congenital heart center * ability to take oral or enteral medication exclusion criteria: * treatment with another investigational drug within 3 months * pre-existing myelosuppression or decreased bone marrow activity. * current or recent treatment with certain drugs * renal or hepatic impairment deemed by the study team * conditions and/or post-operative complications that would increase risk to the patient such as mechanical support (ecmo) or issues in the intensive care unit (icu)

Keywords: fontan colchicine heart surgery
descemet endothelial thickness comparison trial ii

Conditions: Fuchs; Fuchs Dystrophy; Fuchs' Endothelial Dystrophy

Summary: descemet endothelial thickness comparison trial (detect) ii is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with fuchs endothelial dystrophy to dmek versus descemet stripping only (dso) with adjunctive ripasudil.


Eligibility criteria:
inclusion criteria: * dysfunctional endothelium from fecd with few guttata extending beyond 4.5 mm * peripheral endothelial cell count \>1000 cells/mm2 in at least one quadrant * good surgical candidate for either procedure as determined by the surgeon * willingness to participate * age greater than 18 years exclusion criteria: * aphakia, anterior chamber iol or scleral fixated iol in study eye prior to or anticipated during ek * pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment * other primary endothelial dysfunction such as ppmd * visually significant optic nerve or macular pathology * hypotony (intraocular pressure \<10mmhg) * any prior intraocular surgery other than cataract surgery * \>3 clock hours of any anterior or posterior synechiae * \>1 quadrant of stromal corneal vascularization * inability to comply with post-operative instructions (i.e. unable to position) * pregnancy
cell-mediated immunity for prevention of cmv disease

Conditions: Cytomegalovirus Infections

Summary: an open-label randomized controlled trial to adapt the duration of antiviral prophylaxis in d+/r- patients and in r+ patients receiving atg according to the result of the t-track® cmv assay. investigators will include kidney and liver transplant recipients. patients will be randomized during the first month post transplant. in the interventional arm, while the patient is on antiviral prophylaxis, cmi will be monitored every 4 weeks from the 2nd month after transplant. measurement of cmv cmi will be done in real time by using the t-track® cmv assay. the continuation of antiviral prophylaxis will depend on the result of the assay: * t-track positive (patient at lower risk): discontinuation of the antiviral drug * t-track negative (patient at higher risk): continuation of the antiviral drug until the maximal duration of prophylaxis (3 to 6 months) the standard arm will receive a standard fixed duration of antiviral prophylaxis (3 months for r+ thymoglobulin treated-patients and 6 months for d+/r- patients). measurement of cmv cmi by both t-track® cmv and the quantiferon-cmv® assays will be done at the same time points of the interventional arm, but the result will not be known by the investigators. after discontinuation of prophylaxis, patients in both arms will be followed for the development of cmv replication at each visit using the local pcr assay and antiviral therapy will be administered in case of cmv infection according to local guidelines. the co-primary endpoints will be the incidence of cmv disease or antiviral-treated cmv replication during the first 12 months post transplant and the duration of antiviral prophylaxis.


Eligibility criteria:
inclusion criteria: * 18 years old * kidney or liver transplantation * scheduled to receive cmv antiviral prophylaxis: * cmv d+/r- patients * patients receiving lymphocyte-depleting antibodies (thymoglobulin® or atg®) exclusion criteria: * unable to provide informed consent * unable or unwilling to comply with study protocol

Keywords: cell-mediated immunity antiviral prophylaxis transplantation
interest of tumor replicates in avian embryo to model therapeutic effects of brafi/meki in braf mutated melanoma

Conditions: Melanoma

Summary: this is an interventional mono-centric study in patients with braf mutated metastatic melanoma treated with braf/mek inhibitors. the aim of the study is to test the grafting of patient tumoral cells in avian embryo and develop a predictive in vivo model for patient treatment response.


Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years * signed written informed consent * patient with braf v600 mutated metastatic or unresectable melanoma histologically confirmed * brafi/meki treatment indication * patient with skin tumor (excluded face and skinfold) available for biopsy * measurable disease as defined by recist v1.1 criteria * patient affiliated to or a beneficiary of a social security category exclusion criteria: * ocular melanoma * medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study * pregnant or nursing (lactating) women * patients protected by law

Keywords: melanoma avian embryo
consistency of immunogenicity and non inferiority of gsk biologicals' candidate malaria vaccine lots in children

Conditions: Malaria

Summary: the purpose of this study is to show the consistency of different lots of a candidate vaccine (257049) against malaria developed by glaxosmithkline (gsk) biologicals.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parent(s)/legally acceptable representative(s) (lar) can and will comply with the requirements of the protocol. * a male or female child between, and including, 5 and 17 months of age at the time of the first vaccination. * signed or thumb-printed informed consent obtained from the parent(s)/lar(s) of the child. where parent(s)/lar(s) are illiterate, the consent form will be countersigned by a witness. * healthy subjects as established by medical history and clinical examination before entering into the study. * subjects who have received three documented doses of hepatitis b vaccine. exclusion criteria: * same sex twins. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * family history of congenital or hereditary immunodeficiency. * history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. * major congenital defects or serious chronic illness. * history of any neurological disorders or seizures. * moderate or severe malnutrition at screening defined as weight for age z-score less than 2. * acute disease and/or fever at the time of enrolment * acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or medical history. * use of a drug or vaccine that is not approved for that indication other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs since birth. * planned administration/administration of a licensed vaccine not foreseen by the study protocol within 7 days of the first dose of study vaccine. * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * administration of immunoglobulins and/or any blood products within 1 month preceding the first dose of study vaccine or planned administration during the study period. * child in care. * any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.

Keywords: malaria plasmodium falciparum
impact of spectacles on compliance to mask-wearing directives

Conditions: Covid19

Summary: primary objective of this study is to identify the compliance of greek people in mask-wearing directive and explore potential associations with refractive errors, spectacles and contact lenses use.

present study aims to identify whether greek people have complied with mask-wearing directive and to investigate the correlation of outcomes with visual acuity - refractive errors, spectacles and contact lenses use. for the purposes of this research, a questionnaire of 20 items including the following sub scales have been developed: a) near vision, b) distance vision, c) ocular discomfort, d) driving, e) limitations, need for help, work collaboration, and emotional impact

Eligibility criteria:
inclusion criteria: * age \>18 years old * adequate literacy of greek language * permanent residence in greece exclusion criteria: * poor knowledge of greek language

Keywords: face masks spectacles contact lenses compliance in mask-wearing directive
the effect of hyperglycemia on lv function and exercise capacity in diabetics with and without heart failure.

Conditions: Heart Failure; Type 2 Diabetes

Summary: diabetes and heart failure are diseases with high morbidity and increased risk of death. former investigations has shown that diabetes worsens the prognosis of heart failure. however it is uncertain how short term diabetic dysregulation in type 2 diabetics affect cardiac function. our hypothesis is that short term dysregulation affects left ventricular function and exercise capacity in insulin treated type 2 diabetics with and without heart failure. to elucidate this hypothesis diabetic patients with and without heart failure will be investigated after overnight state of either high or normal blood glucose levels on two separate occasions. metabolic and hormonal parameters will be measured. systolic and diastolic cardiac function will be assessed, exercise capacity and post exercise regional myocardial tissue velocity as well as 6 minutes walk test will be investigated on both occasions. the study will be a randomized cross-over design.


Eligibility criteria:
inclusion criteria: * either normal ejection fraction (ef) or heart failure (ef =\<45%) * insulin treated type 2 exclusion criteria: * forme stroke with significant physically or mentally disabilitating disorders * advanced renal disease (creatinine levels \>220 mm) * advanced lever disease (alanine aminotransferase \> 3 times over reference level). * pregnancy * other significant disabilitating disorders
a safety and efficacy study of intravenous e5564 in patients with severe sepsis

Conditions: Sepsis; Shock, Septic; Sepsis Syndrome; Septicemia; Infection

Summary: sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. this infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death. much of the injury is due to endotoxin, a harmful substance produced by certain types of bacteria. an endotoxin antagonist is designed to block the effects of endotoxin. this study is designed to study the safety and efficacy when treating patients with severe sepsis.


Eligibility criteria:
inclusion criteria: * presently admitted, or about to be transferred, to the icu. * women of child-bearing potential must have a negative serum (or urine) hcg assay within 24 hours prior to drug administration. * any race. * severe sepsis \[newly developed respiratory failure, refractory shock, renal dysfunction, hepatic dysfunction, or metabolic acidosis and at least three signs of sirs (systematic inflammatory response syndrome)\]. * objective signs of infection likely to be caused by a bacterial or fungal pathogen. * patients must receive study medication within 8 to 12 hours of recognition of the initial sepsis-related organ failure. * apache predicted risk of mortality score between 20% and 80%. * an intent by physicians and family to aggressively treat the patient for the 28 day study period. exclusion criteria: * cardiogenic or hypovolemic shock. * acute third degree burns involving \>20% of body surface. * recipients of non-autologous organ transplants within the past year. * pregnancy. * chronic vegetative state. * uncontrolled serious hemorrhage (.2 units of blood/platelets in the previous 24 hours). patients may be considered for enrollment if bleeding has stopped and patients are still otherwise qualified. * unwilling or unable to be fully evaluated for all follow-up visits. * patients who are classified as "do not resusitate" or "do not treat." * patients who develop severe sepsis \ 36 hours post-trauma or post-surgery, if they meet other inclusion criteria. * patients with a predicted risk of mortality score of \ 80% after recognition of qualifying organ failure. * patients with a predicted risk of mortality of \<51% for whom xigris® use is planned.

Keywords: sepsis shock septic sepsis syndrome septicemia endotoxins endotoxemia infection
tough talks: a disclosure intervention for hiv+ young men who have sex with men (ymsm)

Conditions: Hiv; HIV/AIDS; Disclosure

Summary: tough talks is a virtual reality based hiv disclosure intervention that allows hiv+ individuals to practice disclosing to romantic partners. tough talks allows participants to have the opportunity to practice disclosing using a variety of strategies and experience different outcomes including acceptance, confusion, lack of hiv knowledge, and rejection.

during phase i of this project, the investigators developed an ipad based virtual reality system that features three avatars, two virtual locations and three disclosure scenarios which represent a variety of common disclosure experiences and contexts experienced by ymsm. in phase ii the investigators will further enhance tough talks and develop a full-feature automated version to test via a multi-site, randomized controlled trial (rct) through the newly created center for innovative technologies (itech) across the prevention and care continuum, an nih-funded center to support adolescent hiv research.

Eligibility criteria:
inclusion criteria: * 16-29 years * assigned male at birth * male identified * hiv infected * owns a mobile device or has access to a laptop or desktop computer * able to understand, read, and speak english * reports 1 or more episodes of anal intercourse with a male partner in the last 6 months exclusion criteria: * hiv negative * assigned female at birth * 15 or younger * 30 or older

Keywords: msm hiv disclosure ehealth virtual reality
a study on the occurrence time of grade-b pancreatic fistula after pancreatoduodenectomy

Conditions: Postoperative Pancreatic Fistula

Summary: to confirm the time point of cr-popf of grade-b that patients with biochemical leak after pd or lpd turned into.

1. to confirm the time point of cr-popf of grade-b that patients with biochemical leak after pd or lpd turned into. 2. establishment of risk assessment model for grade b fistula.

Eligibility criteria:
inclusion criteria: * patients underwent pancreatoduodenectomy (pd) or laparoscopic pancreatoduodenectomy (lpd) surgery. * surgery performed by the same surgical team. exclusion criteria: * pd or lpd combined with another organ resection. * pd or lpd performed due to trauma. * pd or lpd for emergency treatment, such as the rupture and bleeding of tumor. * palliative resection. * patients with severe organ dysfunction before surgery. * patients treated with preoperative neoadjuvant chemotherapy or other treatments (radiotherapy, targeted immunotherapy, etc.). * patients with missing data for clinical or radiographic variables.

Keywords: postoperative pancreatic fistula